Literature DB >> 15926010

Topiramate in migraine prophylaxis.

D D'Amico1, L Grazzi, S Usai, F Moschiano, G Bussone.   

Abstract

This paper reviews results of placebo-controlled trials on topiramate (TPM) prophylaxis in migraine patients, and discusses issues regarding the use of this medication in clinical practice. Data from well conducted double-blind controlled trials and from a comparative trial show that TPM is effective against migraine, confirming the experience of physicians in various countries. Lack of major contraindications, high responder rate, good tolerability at the target dose (100 mg/day) following slow titration, and lack of weight gain make TPM one of the most effective and well accepted drugs for migraine prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15926010     DOI: 10.1007/s10072-005-0425-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  8 in total

1.  Retinal function and histopathology in rabbits treated with Topiramate.

Authors:  S Kjellström; A Bruun; B Isaksson; T Eriksson; S Andréasson; V Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-11-18       Impact factor: 2.379

2.  Topiramate maculopathy secondary to dose titration: first reported case.

Authors:  P S Severn; R Symes; R Rajendram; B Pal
Journal:  Eye (Lond)       Date:  2015-05-01       Impact factor: 3.775

3.  Topiramate and cortical excitability in humans: a study with repetitive transcranial magnetic stimulation.

Authors:  M Inghilleri; F Gilio; A Conte; V Frasca; C Marini Bettolo; E Iacovelli; B Gregori; M Prencipe; A Berardelli
Journal:  Exp Brain Res       Date:  2006-08-05       Impact factor: 1.972

4.  Nephrolithiasis in topiramate users.

Authors:  Naim M Maalouf; Joshua P Langston; Paul C Van Ness; Orson W Moe; Khashayar Sakhaee
Journal:  Urol Res       Date:  2010-12-17

5.  Cost-Effectiveness Analysis of Erenumab Versus OnabotulinumtoxinA for Patients with Chronic Migraine Attacks in Greece.

Authors:  Theodoros V Giannouchos; Dimos-Dimitrios Mitsikostas; Robert L Ohsfeldt; Athanassios Vozikis; Paraskevi Koufopoulou
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

6.  Stroke and migraine.

Authors:  Jesse Weinberger
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-06

Review 7.  Stroke and migraine.

Authors:  Jesse Weinberger
Journal:  Curr Cardiol Rep       Date:  2007-03       Impact factor: 2.931

8.  Interactions between migraine and stroke.

Authors:  Jesse Weinberger
Journal:  Curr Treat Options Neurol       Date:  2006-11       Impact factor: 3.972

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.